Vantrexa · NSCLC · Italy · Oncology pharmacist · captured by Rachel Adeyemi on 23 Jan 2026 · reviewed by Dr. Sophie Laurent on 29 Jan 2026
Marked as duplicate
Verbatim as captured; never edited
Oncology pharmacist at Ospedale San Raffaele raised chemotherapy-free first line during a congress meeting. They requested supporting literature and a follow-up discussion.
Human-approved by Dr. Sophie Laurent on 29 Jan 2026
Chemotherapy-free first line: interest in collaboration reported by oncology pharmacist (IT).
helixor-private-llm-2026.05 · generated 23 Jan 2026, 10:00 UTC
AI summary
Chemotherapy-free first line raised by oncology pharmacist; relevant for Medical Affairs.
Source spans used by the model
Oncology pharmacist at Ospedale San Raffaele raised chemotherapy-free first line during a congress meeting. They requested supporting literature and a follow-up discussion.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Clinical practice | Clinical practice |
| Function | Medical Affairs | Medical Affairs |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 2 | 20% | 8.0 |
| Scientific importance | 5 | 15% | 15.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 2 | 10% | 4.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 54 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
23 Jan 2026 · Dr. Oscar Petit, Ospedale San Raffaele · MSL Rachel Adeyemi
Insight
Reviewed 29 Jan 2026 by Dr. Sophie Laurent
Action
Initiative
Decision
Outcome
Closure
Duplicate theme merged into strategic objective review.
Duplicate of INS-0012 — Patient advocacy groups prioritise fatigue and prognostic uncertainty over proteinuria; current endpoints perceived as not patient-relevant. Supports adding a fatigue PRO to the registry protocol.